stockrowFortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
Follow FTRE
Alert me
Fortrea Holdings Inc. (FTRE) Net income
Fortrea Holdings Inc.'s net income for fiscal 2025 was −$986.2M, compared with −$328.5M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$68.7M. Over the past ten years it has ranged from −$986.2M (fiscal 2025) to $186.2M (fiscal 2022) — the current reading is the lowest in ten years. Net income has fallen for 3 consecutive fiscal years. Fortrea Holdings Inc. ranks 374th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$986.2M | — |
| FY2024 | −$328.5M | — |
| FY2023 | −$25.2M | — |
| FY2022 | $186.2M | 90.00% |
| FY2021 | $98.0M | — |
| FY2020 | −$359.0M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $600.0K | — |
| Jun 2026 | −$13.2M | — |
| Mar 2026 | −$23.6M | — |
| Dec 2025 | −$32.5M | — |
| 15 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | $178.6M |
| TRAX First Tracks Biotherapeutics, Inc. compare | $16.3M |
| FTRE Fortrea Holdings Inc. | −$68.7M |
| SRPT Sarepta Therapeutics, Inc. compare | −$114.6M |
| ZYME Zymeworks Inc. compare | −$150.0M |
| VIR Vir Biotechnology, Inc. compare | −$184.8M |
| IMNM Immunome, Inc. compare | −$254.3M |
| REPL Replimune Group, Inc. compare | −$271.0M |
| BHVN Biohaven Ltd. compare | −$542.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item